



February 2, 2025

**Mailing Address:**

Attn: Jen Laws  
PO Box 3009  
Sidell, LA 70459

**Chief Executive Officer:**

Jen Laws  
Phone: (313) 333-8534  
Fax: (646) 786-3825  
Email: [jen@tiicann.org](mailto:jen@tiicann.org)

**Board of Directors:**

Darnell Lewis, Chair  
Riley Johnson, Secretary  
Dusty Garner, Treasurer

Michelle Anderson  
Hon. Donna Christensen, MD  
Kathie Hiers  
Kim Molnar  
Judith Montenegro  
Amanda Pratter  
Trelvis D. Randolph, Esq  
Cindy Snyder

**Director Emeritus:**

William E. Arnold (*in Memoriam*)  
Jeff Coudriet (*in Memoriam*)  
Hon. Maurice Hinchey, MC (*in Memoriam*)  
Gary R. Rose, JD (*in Memoriam*)

**National Programs:**

340B Action Center  
PDAB Action Center

Transgender Leadership in HIV Advocacy  
HIV/HCV Co-infection Watch

**National Groups:**

Hepatitis Education, Advocacy & Leadership  
(HEAL) Group

Industry Advisory Group (IAG)

National ADAP Working Group (NAWG)

New York State Legislature  
New York Senate Health Committee  
172 State Street, Capitol Building  
Albany, NY 12247  
Via electronic mail

**RE: SB 1913**

Dear Honorable Chairman Rivera, Ranking Member Gallivan, Members of the New York Senate Health Committee, and your respected staff,

The Community Access National Network (CANN) writes in **OPPOSITION** to **SB 1913**, which would expand the federal 340B Drug Pricing Program in New York without sufficient oversight to ensure the program appropriately serves patients, particularly those living with HIV and other chronic health conditions.

The **Community Access National Network (CANN)** is a 501(c)(3) national nonprofit organization focusing on public policy issues relating to HIV/AIDS and viral hepatitis. CANN's mission is to define, promote, and improve access to healthcare services and support for people living with HIV/AIDS and/or viral hepatitis through advocacy, education, and networking.

While CANN is primarily focused on policy matters affecting access to care for people living with and affected by HIV, we stand in firm support of all people living with chronic and rare diseases and recognize the very reality of those living with multiple health conditions and the necessity of timely, personalized care for every one of those health conditions. The 340B Drug Pricing Program is of profound importance to our community.

On May 28th, 2024 the “340B Affording Care for Communities and Ensuring a Strong Safety-net Act” or “340B ACCESS Act” was unveiled in the United States House of Representatives. The bill represents a careful negotiation between a variety of stakeholders affected by the 340B program, including but not limited to the National Association of Community Health Centers, a trade organization representing pharmaceutical manufacturers, and several patient advocacy organizations. CANN is proud to count ourselves among the members working to find consensus on reforming the 340B drug discount program.

**RE: SB 1913**  
**February 2, 2025**  
**Page Two**

**SB 1913** undermines the well-recognized need for reform to align 340B with its original intent because the bill seeks an avenue to [expand 340B contract pharmacy arrangements without limitation](#) – particularly, limitations necessary to ensure proper transparency and accountability.

[The primary harm of contract pharmacies in the 340B program](#) is that they can divert profits intended for low-income patients by allowing large, for-profit retail pharmacies to capitalize on discounted drug prices, potentially leading to less money being reinvested in patient care and a lack of transparency regarding how the savings are being used; this can be considered an abuse of a program designed to help vulnerable populations access affordable medications.

Similarly, diversion of program benefit from needy communities and into wealthier communities is only further enabled when the program is expanded without sufficient guardrails. Unchecked, the 340B has encouraged consolidation, community pharmacy closures, harms rural access, and in an extraordinary example of abuse, [been the driving financing force in mismanaged housing programs that have left patients dead](#).

**SB 1913** poses the potential to exacerbate problems in the 340B program without sufficiently ensuring the expansion actually benefits patients.

If this body seeks to positively impact patient access to care, priority on [PBM reform is a must](#). PBM reform, not unchecked 340B expansion, speaks most directly to patient concerns regarding pharmacy access, benefit design, and medication affordability.

To be clear, CANN supports a strong 340B program. When 340B operates the way it is intended, safety-net providers thrive and vulnerable communities, families, and individuals gain access to healthcare they might otherwise not have. CANN welcomes discussion on instituting appropriate guardrails into legislation that would serve to strengthen the program, shield good stewards, and hold accountable bad actors within the appropriate limitations of state powers associated with this federal program.

We would be happy to discuss this legislation or any other matters of public health, please feel free to reach out by email or phone at [kalvin@tiican.org](mailto:kalvin@tiican.org) , 913-954-8816, or [jen@tiicann.org](mailto:jen@tiicann.org), 313-333-8534.

Respectfully submitted,



Sincerely,  
Calvin Pugh  
Director of State Policy, 340B  
Community Access National Network (CANN)

----

On behalf of  
Jen Laws  
President & CEO  
Community Access National Network